Annotation Detail
Information
- Associated Genes
- TOX3
- Associated Variants
-
FGFR2 c.109+906T>C
(
ENST00000683211.1,
ENST00000357555.9,
ENST00000683035.1,
ENST00000346997.6,
ENST00000369061.8,
ENST00000457416.7,
ENST00000356226.8,
ENST00000684153.1,
ENST00000611527.1,
ENST00000682550.1,
ENST00000613048.4,
ENST00000359354.6,
ENST00000369056.5,
ENST00000360144.7,
ENST00000369059.5,
ENST00000351936.11,
ENST00000369060.8,
ENST00000358487.10 )
rs3803662
FGFR2 c.109+906T>C ( ENST00000683211.1, ENST00000684153.1, ENST00000346997.6, ENST00000351936.11, ENST00000356226.8, ENST00000357555.9, ENST00000358487.10, ENST00000359354.6, ENST00000360144.7, ENST00000369056.5, ENST00000369059.5, ENST00000369060.8, ENST00000369061.8, ENST00000457416.7, ENST00000611527.1, ENST00000613048.4, ENST00000682550.1, ENST00000683035.1 )
rs3803662 - Associated Disease
- Malignant neoplasm of breast
- Source Database
- DisGeNET
- Description
- Odds ratios for breast cancer were greatest for FGFR2-rs2981582 and TNRC9-rs3803662 and, for these 2 SNPs, were significantly greater for estrogen receptor (ER)-positive than for ER-negative disease, both in our data and in meta-analyses of all published data (pooled per-allele ORs [95% confidence intervals] for ER-positive vs ER-negative disease: 1.30 [1.26-1.33] vs 1.05 [1.01-1.10] for FGFR2; interaction P < .001; and 1.24 [1.21-1.28] vs 1.12 [1.07-1.17] for TNRC9; interaction P < .001).
- Pubmed
- 20664043
- Original source reporting the Gene Disease association
- BeFree
- DisGENET score for the Gene Disease association
- 0.170011451031125
- Year of publication
- 2010
Drugs